1. Home
  2. ADPT vs TSLX Comparison

ADPT vs TSLX Comparison

Compare ADPT & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • TSLX
  • Stock Information
  • Founded
  • ADPT 2009
  • TSLX 2010
  • Country
  • ADPT United States
  • TSLX United States
  • Employees
  • ADPT N/A
  • TSLX N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • TSLX Investment Managers
  • Sector
  • ADPT Health Care
  • TSLX Finance
  • Exchange
  • ADPT Nasdaq
  • TSLX Nasdaq
  • Market Cap
  • ADPT 1.8B
  • TSLX 2.1B
  • IPO Year
  • ADPT 2019
  • TSLX 2014
  • Fundamental
  • Price
  • ADPT $10.75
  • TSLX $24.45
  • Analyst Decision
  • ADPT Strong Buy
  • TSLX Strong Buy
  • Analyst Count
  • ADPT 7
  • TSLX 8
  • Target Price
  • ADPT $10.57
  • TSLX $22.69
  • AVG Volume (30 Days)
  • ADPT 2.1M
  • TSLX 474.3K
  • Earning Date
  • ADPT 08-05-2025
  • TSLX 07-30-2025
  • Dividend Yield
  • ADPT N/A
  • TSLX 8.51%
  • EPS Growth
  • ADPT N/A
  • TSLX N/A
  • EPS
  • ADPT N/A
  • TSLX 1.89
  • Revenue
  • ADPT $189,527,000.00
  • TSLX $481,092,000.00
  • Revenue This Year
  • ADPT $24.39
  • TSLX N/A
  • Revenue Next Year
  • ADPT $20.44
  • TSLX N/A
  • P/E Ratio
  • ADPT N/A
  • TSLX $12.95
  • Revenue Growth
  • ADPT 8.61
  • TSLX 4.73
  • 52 Week Low
  • ADPT $3.85
  • TSLX $18.58
  • 52 Week High
  • ADPT $12.43
  • TSLX $25.17
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 48.31
  • TSLX 58.00
  • Support Level
  • ADPT $10.22
  • TSLX $24.13
  • Resistance Level
  • ADPT $11.18
  • TSLX $24.59
  • Average True Range (ATR)
  • ADPT 0.51
  • TSLX 0.31
  • MACD
  • ADPT -0.15
  • TSLX -0.05
  • Stochastic Oscillator
  • ADPT 24.82
  • TSLX 40.98

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: